Patients with the most common form of metastatic breast cancer may soon have a powerful new all-oral treatment option. Results from the phase 3 evERA Breast Cancer study, published in the New England Journal of Medicine, show that adding giredestrant, a next-generation selective estrogen receptor degrader, to the mTOR inhibitor everolimus significantly extended the time patients lived without their disease worsening compared with a standard combination regimen. The findings address one of the most pressing unmet needs in oncology: what to do for patients whose estrogen-receptor-positive breast cancer has stopped responding to the therapies that once controlled it.
Estrogen-receptor-positive tumors account for roughly 70 percent of all breast cancers, making this the single largest subgroup of patients with metastatic disease. These tumors carry receptors that respond to the hormone estrogen, which acts as a growth signal, driving cancer cells to proliferate. For decades, the central strategy against them has been endocrine therapy, which blocks estrogen signaling in one way or another. But when the disease spreads beyond the breast, treatment becomes far more difficult, and resistance to hormonal agents eventually emerges in nearly every patient.
The landscape changed dramatically with the arrival of CDK4/6 inhibitors, drugs that shut down enzymes cancer cells rely on to progress through the cell division cycle. Combined with endocrine therapy, these agents greatly improved outcomes for patients with metastatic disease and became a global standard of care. Yet the benefit is not permanent. Once a tumor progresses through CDK4/6 inhibition, the options that remain are often limited, less effective, and associated with burdensome side effects. It is precisely this post-CDK4/6 setting that the evERA study was designed to target.
Giredestrant belongs to a class of drugs known as selective estrogen receptor degraders, or SERDs. Unlike conventional endocrine therapies that simply block the receptor, a SERD binds directly to the estrogen receptor and promotes its degradation, physically removing the molecular target that estrogen would otherwise activate. As a full antagonist, giredestrant not only eliminates the receptor but also blocks any residual activity. Because it is taken orally, it offers a convenient alternative to earlier injectable degraders such as fulvestrant, and its next-generation design aims to deliver more complete receptor suppression with a manageable safety profile.
The evERA trial paired giredestrant with everolimus, an inhibitor of mTOR, a protein kinase that sits downstream of growth-signaling pathways and that tumors frequently exploit to survive despite endocrine treatment. Everolimus is already approved in combination with endocrine therapy for this patient population, so the study asked a pointed question: does replacing the endocrine backbone with a superior receptor degrader improve results when the mTOR blockade is held constant? Notably, evERA was the first phase 3 study to compare a novel combination strategy head-to-head against a standard-of-care combination regimen in this setting, rather than testing a new drug alone against a single agent.
The trial enrolled 373 patients with ER-positive, HER2-negative advanced breast cancer, all of whom had previously received treatment. Participants were randomly assigned in a global, open-label design to receive either the oral combination of giredestrant plus everolimus or a standard-of-care endocrine therapy plus everolimus. Importantly, about 55 percent of the enrolled patients carried mutations in ESR1, the gene that encodes the estrogen receptor itself. These mutations, which commonly arise under the pressure of prior endocrine therapy, alter the receptor’s structure so that it becomes active even without estrogen, a classic mechanism of treatment resistance. The trial was powered to evaluate progression-free survival both in the overall intention-to-treat population and in the ESR1-mutated subgroup specifically.
The results in the ESR1-mutated subgroup were striking. With a median follow-up of 18.6 months, patients whose tumors harbored an ESR1 mutation and who received the giredestrant-containing regimen achieved a median progression-free survival of 10 months, compared with 5.5 months for those on the standard combination. That difference corresponds to a 63 percent reduction in the risk of disease progression or death, a near doubling of the time patients lived without their cancer advancing. In a disease setting where each additional month of control matters enormously to patients and clinicians alike, the magnitude of the effect stood out even to the investigators who designed the study.
The benefit extended across the entire trial population as well. In the intention-to-treat analysis, which included patients with and without ESR1 mutations, those treated with giredestrant plus everolimus reached a median progression-free survival of 8.8 months versus 5.5 months with the standard-of-care combination, translating to a 44 percent reduction in the risk of progression or death. The consistency of the signal across both the mutation-positive subgroup and the broader population suggests that the regimen’s advantage is not confined to a single molecular subset, although the effect was clearly most pronounced where ESR1 mutations had driven resistance.
Safety data offered reassurance that the efficacy gains did not come at an unacceptable cost. The safety profile of the giredestrant regimen was described as manageable and consistent with the known profiles of the individual study treatments, an important consideration given that everolimus is already associated with side effects such as mouth sores, fatigue, and metabolic changes that can complicate long-term use. Overall survival data from the study remain immature, meaning not enough time has passed for a definitive analysis, but the investigators reported that the trends are favorable, leaving open the possibility that the progression-free survival benefit may eventually translate into longer lives.
For the field, the evERA results signal a shift in how resistance to endocrine therapy might be tackled in metastatic breast cancer. By combining a degrader engineered to eliminate even mutated estrogen receptors with an agent that blocks a parallel survival pathway, the regimen attacks the disease through complementary mechanisms at once. Erica Mayer, Director of Breast Cancer Clinical Research at Dana-Farber Cancer Institute and principal investigator of the study, emphasized that there is an urgent need for more effective therapies for patients whose tumors develop resistance to current endocrine treatments and who have progressed after CDK4/6 inhibitors, and that the published results show a novel combination regimen can substantially improve disease control compared with a standard regimen, potentially benefiting a large number of patients with advanced breast cancer. The study was funded by F. Hoffmann-La Roche Ltd., and with the full publication in the New England Journal of Medicine, the giredestrant-everolimus combination now stands as one of the most consequential advances to date for patients facing metastatic hormone-receptor-positive disease.
Subject of Research: A phase 3 trial of giredestrant plus everolimus for ER-positive, HER2-negative metastatic breast cancer after CDK4/6 inhibitor therapy
Article Title: Novel treatment combination improves progression-free survival in most common form of metastatic breast cancer
Article References: Novel treatment combination improves progression-free survival in most common form of metastatic breast cancer. (n.d.). Original publication
Image Credits: AI Generated
DOI: Not provided
Keywords: giredestrant, everolimus, SERD, metastatic breast cancer, ER-positive, ESR1 mutation, progression-free survival, CDK4/6 inhibitors, endocrine therapy resistance, phase 3 trial, evERA study, New England Journal of Medicine
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (October 3, 2026). Oral Giredestrant Combination Nearly Doubles Survival Without Progression in Metastatic Breast Cancer. Scienmag. https://scienmag.com/oral-giredestrant-combination-nearly-doubles-survival-without-progression-in-metastatic-breast-cancer/
Nathaniel Bowman. “Oral Giredestrant Combination Nearly Doubles Survival Without Progression in Metastatic Breast Cancer.” Scienmag, 3 October 2026, https://scienmag.com/oral-giredestrant-combination-nearly-doubles-survival-without-progression-in-metastatic-breast-cancer/. Accessed 3 October 2026.
Nathaniel Bowman. “Oral Giredestrant Combination Nearly Doubles Survival Without Progression in Metastatic Breast Cancer.” Scienmag. October 3, 2026. https://scienmag.com/oral-giredestrant-combination-nearly-doubles-survival-without-progression-in-metastatic-breast-cancer/
Copy citation Download RIS
Tags: CDK4/6 inhibitorsendocrine therapy resistanceER-positiveESR1 mutationestrogen receptor-positive breast cancerevERA studyeverolimusgiredestrantgiredestrant and everolimus combinationhormone receptor-positive tumorsMetastatic Breast Cancermetastatic breast cancer treatmentmTOR inhibitors in breast cancerNew England Journal of Medicinenovel oral breast cancer therapiesovercoming treatment resistancephase 3 evERA studyphase 3 trialProgression-Free Survivalselective estrogen receptor degraderSERDtargeted therapy for metastatic disease
